acute

TREATMENT

Oral Gepants Have Disrupted Acute Migraine Management and Look Next to Transform Preventive Treatment, According to Both Primary Care Physicians and Specialists | Surveys Polls And Research

EXTON, Pa., May 6, 2021 /PRNewswire/ — Both AbbVie’s (formerly Allergan, an AbbVie company) Ubrelvy and Biohaven’s Nurtec ODT are viewed by primary care physicians (PCPs) as strong entrants into the acute segment of the migraine market following their early 2020 launches. Interestingly, a new study from Spherix found similar physician-reported shares for both gepants [i.e., oral calcitonin gene-related peptide (CGRP) receptor antagonists], despite Ubrelvy’s earlier launch.  

In the inaugural semiannual report included in Spherix’s RealTime Dynamix™: Migraine – PCP Perspective (US) service, data collected from 96 PCPs found that, of the two gepants, direct comparison gives Nurtec ODT the advantage over Ubrelvy on most clinical metrics. Nurtec ODT best differentiates from Ubrelvy on duration of effect and convenience of patient administration among PCPs, consistent with its prevention label currently under FDA review and its unique orally dissolving tablet formulation, respectively.

Spherix has also been tracking the specialist-treated (i.e.,

Read More Read More
THERAPY

Hydrogen therapy for Covid-19 acute respiratory distress syndrome (ARDS) | by Vaibhav

Vaibhav
Covid-19 rendering

In the cohort involving 201 patients with confirmed COVID-19 pneumonia, risk factors associated with the development of acute respiratory distress syndrome (ARDS) and progression from ARDS to death included older age, neutrophilia and organ and coagulation dysfunction. Recently, accumulating evidence suggests that a subgroup of patients with severe COVID-19 might have a cytokine storm syndrome and hyper inflammation. [1,2]

[A] Prof. Zhong Nanshan, Chinese scientist, epidemiologist and pulmonologist who discovered the SARS coronavirus in 2003 on benefits of the oxygen-hydrogen gas mix inhalation in Chinese patients

[B] Overview of planned or ongoing studies of drugs for the treatment of COVID-19

Hydrogen-oxygen nebulizer

[C] Duried Alwazeer, Redox Research Center, Igdir Üniversitesi on Potential Cheap and effective Drug for COVID-19

https://www.researchgate.net/post/Potential_Cheap_and_effective_Drug_for_COVID-19

Given the theory that molecular hydrogen can significantly down-regulate expressions of inflammation-related genes and selectively reduce hydroxyl radical, there are reasons to believe that cytokine storm

Read More Read More